Table 2.
Summary of reported clinical response to TKIs in patients harboring the single EGFR S768I mutation
| Author | Year | n | Nationality | Age | Sex | Smoking | Stage | EGFR-TKI | Prior therapy | Line | RECIST | PFS |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Masago et al34 | 2010 | 1 | Japanese | 81 | M | 37 pack-years | IV | Gefitinib | – | 2 | PR | 461 days |
| Lund-Iversen et al35 | 2012 | 1 | Norwegian | 73 | F | Former | IV | Erlotinib | Chemotherapy | 2 | PD | 1 month |
| Weber et al36 | 2014 | 1 | Danish | – | – | IV | Erlotinib | Chemotherapy | 2 | PD | 1 month | |
| Hellmann et al19 | 2014 | 1 | American | – | – | 5 pack-years | IV | Erlotinib | – | 1 | PR | 8 years |
| Pallan et al37 | 2014 | 2 | Afro-Caribbean Caucasian |
56 65 |
M F |
1 pack-year 20 pack-years |
IV IV |
Gefitinib Erlotinib |
– Chemotherapy |
1 2 |
PD PD |
6 weeks 2 months |
| Chiu et al38 | 2015 | 6 | Taiwanese | – | – | – | – | Gefitinib or erlotinib | – | – | 2PD, 2PR, 2SD | – |
| Heigener et al39 | 2015 | 1 | German | – | – | – | – | Afatinib | – | – | SD | – |
| Yang et al40 | 2015 | 1 | Chinese | 56 | F | – | IV | Afatinib | – | 1 | PR | 5 months |
| Yang et al11 | 2015 | 1 | – | – | – | – | – | Afatinib | – | – | PR | – |
| Leventakos et al41 | 2016 | 1 | – | – | – | – | IV | Gefitinib | – | – | PD | 3 months |
| Klughammer et al42 | 2016 | 1 | – | – | – | – | – | Erlotinib | – | – | PR | – |
| Cheng et al43 | 2016 | 1 | Chinese | 59 | F | – | IV | 1G-TKI | – | – | PR | 8.6 months |
| Kobayashi et al44 | 2016 | 1 | Japanese | 61 | F | – | IV | Afatinib | – | 11 | PR | 12 months |
| Zhang et al45 | 2017 | 1 | Chinese | 64 | M | – | – | Icotinib | – | 2 | SD | 31 months |
| Zhu et al46 | 2017 | 1 | Chinese | 52 | F | – | IIIa | Gefitinib | – | 1 | SD | 8.8 months |
| Russo et al32 | 2017 | 1 | Italian | 65 | M | – | IV | Afatinib | – | 1 | PR | 3 months |
Abbreviations: 1G, first-generation; EGFR, epidermal growth factor receptor; F, female; M, male; PD, progressive disease; PFS, progression-free survival; PR, partial response; RECIST, response evaluation criteria in solid tumors; SD, stable disease; TKI, tyrosine kinase inhibitor.